Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies primarily in the areas of oncology, neurology, and immunology in the United States and internationally. Its product portfolio comprises AVONEX and TYSABRI for the treatment of relapsing forms of multiple sclerosis; RITUXAN for the treatment of relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphomas, or B-cell NHLs; ZEVALIN, a radio immunotherapy for relapsed o ...